CME Information: Concentrated Insulins

Concentrated Insulins in Clinical Practice: Pharmacology and Treatment Designs


Presented by Joslin Diabetes Center in Joint Providership with PlatformQ Health Education, LLC.

This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.


The activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Joslin Diabetes Center and PlatformQ Health Education, LLC. Joslin Diabetes Center is accredited by the ACCME to provide continuing medical education for physicians.

Live Internet Activity

Joslin Diabetes Center designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Enduring Material
Joslin Diabetes Center designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Live Internet Activity
Wednesday, June 21, 2017, from 12:00 PM EST – 1:00 PM EST
Enduring Material
The enduring material will be available from June 21, 2017 – December 21, 2017.

At the conclusion of this activity, participants will be able to:

Compare the pharmacokinetic and pharmacodynamic properties of concentrated insulins that are used to treat people with diabetes, particularly those with significant insulin resistance
Recognize the indications for and methods to utilize concentrated insulins to treat type 2 diabetes, including people with significant insulin resistance
Identify barriers preventing the use of concentrated insulins in one’s own practice, as well as area primary care practices, and enhance skills in mentoring the use of these treatment tools when indicated


Primary Audience:
Clinically focused diabetes specialty care providers, including diabetologists, endocrinologists, and internists with a heavy practice focus on diabetes. These providers consist of physicians, nurse practitioners and physician assistants who work in specialty practices.
Secondary Audience:
Certified diabetes educators and pharmacists with significant numbers of patients/clients with diabetes and non-diabetes specialty physicians who care for a significant number of people with diabetes and insulin resistance and who might be involved in design or management of glycemic control programs, including general internists, cardiologists and nephrologists.

There are no fees to participate in this activity. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the posttest and activity evaluation. It is estimated that this module will take approximately 1 hour to complete. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the posttest.

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

As part of its accreditation with the Accreditation Council for Continuing Medical Education, Joslin Diabetes Center must disclose to the audience of a Joslin continuing medical education activity the existence of any relevant financial relationships between Joslin and/or its planning and/or CME advisory committee members, speakers, and their spouses/partners and commercial entities. Joslin and its planning and CME advisory committee members and speakers must disclose any relationships they and their spouses/partners have or have had in the prior 12 months with proprietary entities producing healthcare goods or services, with the exception of nonprofit or government organizations and non–healthcare–related companies, which are exempt.

Financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fees, honoraria, ownership interests (e.g., stocks, stock options, or other ownership interest, excluding diversified mutual funds), or other financial benefit in any amount. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received or expected.

If a faculty or planning committee member has no information to disclose, this information will also be provided. If a faculty or planning committee member refuses to disclose, he/she will not be able to participate in the planning, management, presentation, or evaluation of any Joslin Diabetes Center CME activity. In addition, faculty have been asked to disclose when a product or device is not labeled for the use under discussion. The opinions and comments expressed in this program are those of the speakers and should not be considered the opinions or comments of Joslin Diabetes Center.

The faculty and planning committee members for this program have disclosed the following:


  • Dr. Richard S. Beaser*† , Senior Staff Physician and Medical Director of Professional Education, Joslin Diabetes Center, has no relevant financial relationships with regard to this activity.
  • Alissa Segal, PharmD, CDE† , is on the scientific advisory board for Eli Lilly and Co., Inc. and Boehringer Ingelheim Pharmaceuticals, Inc.
  • Wendy Lane, MD, receives grant / research funding from Novo Nordisk, Inc., Lexicon, Inc., Mylan Pharmaceuticals, DexCom, Inc., and Eli Lilly.

Planning Committee

  • Agnes Yang, MD, Medical Director, PlatformQ Health Education, has no relevant financial relationships.
  • Karen Greb-Murphy, Program Manager, PlatformQ Health Education, has no relevant financial relationships.

Joslin CME Advisory Committee

  • Jerry Cavallerano, OD, Optometrist, Beetham Eye Institute, Joslin Diabetes Center, has no relevant financial relationships.
  • Erin Kelly, CDE, Adult Diabetes Educator, Joslin Diabetes Center, is a contract pump trainer for Medtronic, Tandem, Omnipod and Animas.
  • Melinda Maryniuk, CDE, Director, Clinical Programs, Joslin Diabetes Center, has no relevant financial relationships.
  • Lyle Mitzner, MD, Staff Physician, Joslin Diabetes Center, is a consultant for Conversa Health.
  • Robert C. Stanton, MD, Chief of Nephrology, Joslin Diabetes Center, is a consultant for and receives grant / research funding from Boehringer Ingelheim Pharmaceuticals, Inc.
  • Elena Toschi, MD, Staff Physician, Joslin Diabetes Center, has no relevant financial relationships.

* Also on the Planning Committee
† Also on the CME Advisory Committee

Please send content inquiries to: cme@joslin.harvard.edu

For technical problems with the site or issues with your CME Certificate, please contact DiabetesSeriesLive at 877-394-1306 or at Support@DiabetesSeriesLive.com.

DISCLAIMERS (if applicable):
The material is prepared based on a review of multiple sources of information but is not exhaustive of the subject matter. Therefore, health care professionals and other individuals should review and consider other publications and materials about the subject matter other than relying solely on the information contained in this material.

The information presented at this CME program represents the views and opinions of the individual presenters, and does not constitute the opinion or endorsement of, or promotion by Joslin Diabetes Center, DiabetesSeriesLive, PlatformQ Health Education, LLC or the program grantor. Reasonable efforts have been made to present educational subject matter in a balanced, unbiased fashion and in compliance with regulatory requirements. Each participant must use his/her personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.